ArticleMetabolic brain disease2026
Punica granatum L. peel extract mitigates hyperlipidemia-induced cognitive impairments in zebrafish larvae via modulating LXR signaling.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Punica granatum L. is known to provide multiple health benefits against several diseased conditions, primarily hyperlipidemia, atherosclerosis, hyperglycemia and cognitive impairments. Many of its health benefits are attributed due to its antioxidant and anti-inflammatory properties. The purpose of the current study was to assess the in vivo effectiveness of an aqueous peel extract of Punica granatum (PuAq) against hyperlipidemia-induced cognitive impairments in a zebrafish larva model. The quantification of major bioactive metabolites of PuAq was done by a high-pressure liquid chromatography technique. The molecular association of the identified metabolites were assessed through in silico docking simulations. The lower confidence limit of the benchmark dose for PuAq in larvae was calculated to be 59.40 µg/mL. Thereafter, larvae at 4 days' post-fertilization were exposed to a 0.1% egg yolk solution with or without PuAq for the subsequent 5 days. Oil Red O staining showed reduced lipid deposition following PuAq treatment. Furthermore, PuAq incubation alleviated hyperlipidemia-induced cognitive decline in larvae subjected to the partition preference test. The extract treatment increased NeuN protein and bdnf expression within the larvae's cephalic region. The treatment modulated the expression of inflammation, oxidative stress, and lipid metabolism-related genes and reduced lipid peroxidation. The protective effects of PuAq were reverted following pre-exposure of GSK2033 (LXR antagonist), which suggested the involvement of LXR receptor activation for the observed changes. In silico docking simulations further supported the molecular interactions between the identified compounds of PuAq and LXR. The study concluded that PuAq protects against hyperlipidemia-induced cognitive impairments in zebrafish larvae.
Indexed as
Identifiers
42821052What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.